Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: squadrilli a. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G, Minari R, Zecca A, Cavazzoni A, Ferri V, Mori C, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Missale G, Petronini PG, Quaini F, Tiseo M. Mazzaschi G, et al. Among authors: squadrilli a. Lung Cancer. 2020 Oct;148:1-11. doi: 10.1016/j.lungcan.2020.07.028. Epub 2020 Aug 2. Lung Cancer. 2020. PMID: 32768804
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M. Facchinetti F, et al. Among authors: squadrilli a. Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175. Immunotherapy. 2018. PMID: 29882691
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Among authors: squadrilli a. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Minari R, Gnetti L, Lagrasta CA, Squadrilli A, Bordi P, Azzoni C, Bottarelli L, Cosenza A, Ferri L, Caruso G, Silini EM, Tiseo M. Minari R, et al. Among authors: squadrilli a. Transl Lung Cancer Res. 2020 Jun;9(3):787-792. doi: 10.21037/tlcr.2020.04.03. Transl Lung Cancer Res. 2020. PMID: 32676339 Free PMC article.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG, Abbati F, Facchinetti F, Massucci M, Melotti B, Squadrilli A, Buti S, Formica F, Tiseo M, Ardizzoni A. Dall'Olio FG, et al. Among authors: squadrilli a. Ther Adv Med Oncol. 2020 Oct 31;12:1758835920952994. doi: 10.1177/1758835920952994. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33193825 Free PMC article.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Verzè M, Minari R, Gnetti L, Bordi P, Leonetti A, Cosenza A, Ferri L, Majori M, De Filippo M, Buti S, Gasparro D, Nizzoli R, Azzoni C, Bottarelli L, Squadrilli A, Mozzoni P, Tiseo M. Verzè M, et al. Among authors: squadrilli a. Cancers (Basel). 2021 Oct 28;13(21):5403. doi: 10.3390/cancers13215403. Cancers (Basel). 2021. PMID: 34771566 Free PMC article.
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M. Bersanelli M, et al. Among authors: squadrilli a. J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31. J Thorac Oncol. 2016. PMID: 27257132 Free article. No abstract available.
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, Azzoni C, Lagrasta CAM, Gnetti L, Campanini N, Petronini PG, Alfieri R, Tiseo M. Minari R, et al. Among authors: squadrilli a. J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27. J Thorac Oncol. 2018. PMID: 29596911 Free article. No abstract available.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Cinausero M, Laprovitera N, De Maglio G, Gerratana L, Riefolo M, Macerelli M, Fiorentino M, Porcellini E, Buoro V, Gelsomino F, Squadrilli A, Fasola G, Negrini M, Tiseo M, Ferracin M, Ardizzoni A. Cinausero M, et al. Among authors: squadrilli a. Ther Adv Med Oncol. 2019 Nov 14;11:1758835919885540. doi: 10.1177/1758835919885540. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31798692 Free PMC article.
17 results